Gene Expression Analysis for HS Severity Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hidradenitis suppurativa (HS) is often misdiagnosed and underdiagnosed, leading to significant delays in treatment, and current treatments are not curative, with severity-dependent management that can be ineffective in preventing disease progression.
Innovation Solution
Determining gene expression levels of specific genes such as S100A7, S100A8, S100A9, STAT1, NFATC3, BTK, CXCR4, CD86, CD247, CD3D, HLA-DMA, IL6, IL4R, CD79A, CCL27, dermcidin, and IL-37 to characterize HS severity, followed by administering antibiotics, retinoids, steroids, or anti-inflammatory agents tailored to the severity stage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gene expression analysis is performed to accurately characterize HS severity, then treatment precision is improved, but diagnostic complexity and time are increased
Solution Approach 1:
The diagnostic approach is segmented into two distinct pathways: a rapid clinical assessment method using established Hurley staging criteria for immediate treatment decisions, and a detailed molecular profiling method using gene expression analysis for complex or refractory cases. This segmentation allows the system to achieve high measurement precision when needed while avoiding unnecessary complexity in routine cases.
Solution Approach 2:
Different diagnostic approaches are applied to different patient populations based on their specific needs. Simple cases receive streamlined clinical assessment, while complex cases with atypical presentation or treatment resistance receive comprehensive gene expression analysis. This local quality approach ensures measurement precision is applied where most needed while minimizing overall system complexity.
2Reliability
If gene expression analysis is performed to accurately characterize HS severity, then treatment effectiveness is improved, but diagnostic time is increased
Solution Approach 1:
The system performs preliminary clinical assessment using Hurley staging criteria to establish an initial diagnosis and begin appropriate treatment immediately. Gene expression analysis is then performed as a supplementary tool to refine the diagnosis and adjust treatment for complex cases. This preliminary action approach ensures that treatment begins without delay while still allowing for optimized treatment selection.
Solution Approach 2:
The diagnostic system applies partial gene expression analysis (focusing on key inflammatory pathway genes) rather than comprehensive genomic profiling, achieving sufficient treatment effectiveness for clinical decision-making without the full time cost of complete molecular characterization. This partial action approach balances reliability improvement with time loss minimization.
3Reliability
If stage-specific treatments are administered based on HS severity, then disease progression prevention is improved, but treatment complexity is increased
Solution Approach 1:
The treatment regimen is made dynamic and adaptive, allowing escalation or de-escalation based on disease severity and response. Mild cases receive simplified topical therapies, while moderate to severe cases receive systematic combination therapies including antibiotics, anti-inflammatories, and biologic agents. This dynamic approach improves disease progression prevention while managing treatment complexity through structured escalation protocols.
Solution Approach 2:
Treatment parameters are systematically adjusted based on Hurley staging: Stage I receives monotherapy with antibiotics or topical agents, Stage II receives combination therapy with adjusted dosing, and Stage III receives aggressive multi-modal therapy including biologics. This parameter changes approach improves progression prevention by matching treatment intensity to disease severity while organizing complexity into manageable stages.
4Ease of operation
If current standard treatments are used without severity characterization, then treatment simplicity is maintained, but disease progression control is worsened
Solution Approach 1:
The patient population is segmented by disease severity using Hurley staging criteria, with each segment receiving appropriately tailored treatment. This segmentation maintains simplicity within each group while improving overall progression control by ensuring severe cases receive aggressive therapy rather than simplified regimens. The segmentation creates clear treatment algorithms that are simple to follow but effective across different disease severities.
Solution Approach 2:
The Hurley staging system serves multiple functions simultaneously: it provides disease severity classification, guides treatment selection, predicts prognosis, and enables clinical trial enrollment criteria. This multi-functionality maintains treatment simplicity by using a single unified system rather than requiring separate assessments for each purpose, while improving progression control through comprehensive severity-based management.
Data Source
AI summary
Disclosures herein encompass methods of treating a subject with moderate to severe hidradenitis suppurativa (HS) encompassing the determination of differential gene expression to characterize HS severity followed by administration of a treatment specific for the stage of HS severity characterized in the subject.